This is a very rare, inherited (autosomal recessive) disorder caused by harmful changes in a gene called SCYL1. Children with this condition can have repeated episodes of acute liver failure (often in infancy or early childhood), plus problems with balance and coordination (cerebellar ataxia) and damage to the peripheral nerves that carry signals to and from the limbs (sensorimotor neuropathy). Brain MRI may show cerebellar atrophy, and nerve testing usually shows an axonal sensorimotor neuropathy. Liver episodes are commonly triggered by fever or infections and can recover completely between attacks, though some children develop chronic liver scarring over time. Neurological features—unsteady gait, tremor, lower-leg weakness, foot drop, and reduced sensation—tend to be slowly progressive. The syndrome results from disturbances in intracellular trafficking (how proteins move inside cells), especially affecting liver cells and Purkinje cells in the cerebellum. Management focuses on rapid, specialist-led care during liver crises and ongoing rehabilitation and support for movement and nerve symptoms. PMC+1PubMedWJGNetOrpha
This is a very rare genetic condition that starts in infancy. Children have sudden attacks of severe liver failure that may follow fevers or common infections. Between attacks the liver can look better, but scarring can slowly build up. The nervous system is also affected. Children develop balance problems from the cerebellum (ataxia) and later signs of damage to the long nerves of the legs and arms (peripheral neuropathy) with weakness, numbness, or foot-drop. The condition is inherited in an autosomal recessive way and is caused by harmful changes (variants) in a gene called SCYL1. GARD Information CenterNCBINatureScienceDirect
Other names
This disorder is known by several names in medical sources. Common synonyms are CALFAN syndrome (low γ-glutamyl-transferase cholestasis, acute liver failure, and neurodegeneration), SCAR21 (Spinocerebellar ataxia, autosomal recessive 21), and autosomal recessive spinocerebellar ataxia with hepatopathy. It also appears as acute infantile liver failure–cerebellar ataxia–peripheral sensory-motor neuropathy syndrome in rare-disease catalogs. All of these labels describe the same clinicogenetic entity in which biallelic SCYL1 variants cause recurrent acute liver failure in infancy and a later neurodegenerative picture with cerebellar atrophy and peripheral neuropathy. The inheritance pattern is autosomal recessive. NCBINational Organization for Rare DisordersEurope PMC
Types
There is no official subtype system yet, but published case series show a spectrum. It helps to think in simple clinical patterns:
Hepatic-predominant early pattern. Recurrent, fever-triggered acute liver failure or low-GGT cholestasis in infancy with near-normal intervals; neurologic signs appear later. NatureEurope PMC
Mixed hepato-neurologic pattern. Liver crises plus early motor delay, gait imbalance, and tremor; brain MRI often shows stable cerebellar vermis atrophy. GARD Information Center
Neurologic-predominant later pattern. Milder or fewer hepatic episodes but clearer progressive peripheral neuropathy (often axonal), ataxia, and sometimes neurogenic stuttering; mild intellectual disability may occur. GARD Information Center
These patterns reflect variable expression of the same SCYL1-related disease, not different diseases. NCBI
Causes
Read these as simple, evidence-based “why/how” contributors. The primary cause is genetic; several items describe downstream biology or known triggers.
Biallelic SCYL1 variants (autosomal recessive). The essential cause; both copies of the gene carry pathogenic changes. NCBI
Defective SCYL1 (NTK-like) protein function. SCYL1 helps Golgi/secretory-pathway trafficking; loss disrupts cellular protein handling. ScienceDirect
Low-GGT cholestasis physiology. A hallmark liver pattern in CALFAN; bile flow is impaired but γ-GT stays low. Nature
Recurrent acute liver failure biology. Vulnerable hepatocytes decompensate during stress, leading to jaundice, coagulopathy, and encephalopathy. Nature
Cerebellar neurodegeneration. Preferential involvement of the cerebellar vermis produces ataxia and abnormal eye movements. ScienceDirectGARD Information Center
Peripheral axonal neuropathy. Long motor and sensory nerves degenerate, causing distal weakness, numbness, and reduced reflexes. ScienceDirect
Febrile illness as a trigger. Liver crises often follow common infections and fever. Nature
Metabolic/catabolic stress. Fasting, dehydration, or intercurrent illness can unmask hepatic vulnerability (inferred from crisis timing). Nature
Oxidative and ER-stress pathways. Secretory-pathway dysfunction is thought to increase cellular stress in liver and neurons (mechanistic inference from SCYL1 role). ScienceDirect
Progressive liver fibrosis after repeated injury. Scarring accumulates between attacks. sites.uclouvain.be
Hepatosplenomegaly secondary to fibrosis/cholestasis. A downstream change seen in some patients. GARD Information Center
Developmental susceptibility of the infant liver. Immature metabolic reserve increases risk of failure during stress (general pediatric liver-failure principle applied to CALFAN). OAText
Genotype–phenotype variability. Different SCYL1 variants can modulate severity/onset. ScienceDirect
Variable neurologic timing. Neuropathy often appears later than hepatic disease. Nature
Cerebellar vermis atrophy on MRI. A structural marker tied to coordination problems. ScienceDirect
Optic nerve thinning (some cases). A reported associated finding. Global Genes
Neurogenic speech changes (stuttering). Described in some patients with cerebellar/brainstem involvement. GARD Information Center
Possible anesthesia sensitivity. Rare-disease anesthesia notes advise caution because of hepatic reserve and neuropathy. sites.uclouvain.be
Consanguinity/family history. Increases the chance of two SCYL1 variants meeting in a child (general recessive-inheritance principle reflected in case clusters). ScienceDirect
Misdiagnosis or delayed diagnosis. Because it is ultra-rare, missed recognition can allow repeated crises and cumulative damage. (Inferred from rarity reports.) Orpha
Common symptoms and signs
Episodes of acute liver failure in infancy. Sudden jaundice, bleeding tendency, and lethargy; often after fever. Nature
Low-GGT cholestasis between or during crises. Dark urine, pale stools, itching may occur. Nature
Progressive liver scarring with hepatosplenomegaly. Enlarged liver and spleen can appear over time. GARD Information Center
Motor delay in early childhood. Sitting, standing, or walking later than peers. GARD Information Center
Cerebellar ataxia. Unsteady, wide-based gait; clumsy hand movements; intention tremor. ScienceDirect
Abnormal eye movements (dysmetric saccades). Eyes overshoot or undershoot targets. GARD Information Center
Peripheral sensory symptoms. Numbness, tingling, or reduced vibration sense, usually in the feet first. ScienceDirect
Peripheral motor symptoms. Distal weakness, foot-drop, reduced ankle reflexes. ScienceDirect
Neurogenic stuttering or speech difficulty. Reported in some children. GARD Information Center
Mild intellectual disability (some). Learning difficulties may occur. GARD Information Center
Fevers preceding hepatic crises. Parents often notice a cold/fever before jaundice. Nature
Failure to thrive or poor weight gain. During or after liver episodes. GARD Information Center
Fatigue and reduced stamina. From liver disease and neuropathy. GARD Information Center
Visual issues (some). Optic nerve thinning can be present. Global Genes
Normal intervals between attacks early on. The child may look well between episodes, especially in the first years. sites.uclouvain.be
Diagnostic tests
A) Physical examination (bedside clues)
General look and vitals. Fever, lethargy, and dehydration can signal a crisis; growth chart may show poor gain. Clinicians correlate timing with infections. Nature
Skin and eyes. Jaundice, scratch marks (itching), and bruising suggest cholestasis and coagulopathy. Nature
Abdominal exam. Enlarged liver and spleen point to chronic damage between crises. GARD Information Center
Gait and coordination exam. Wide-based gait, intention tremor, and poor heel-to-toe walking reflect cerebellar involvement. ScienceDirect
Neurologic reflexes and sensation. Reduced ankle reflexes and distal vibration loss suggest axonal neuropathy. ScienceDirect
B) Manual bedside neurologic tests (simple office tests)
Finger-to-nose and heel-to-shin. Wobble or overshoot confirms limb ataxia from cerebellar disease. ScienceDirect
Romberg test. Worsening sway with eyes closed hints at sensory ataxia from neuropathy. ScienceDirect
Tandem gait. Difficulty walking heel-to-toe shows midline cerebellar dysfunction. ScienceDirect
Monofilament/vibration testing. Reduced light-touch and vibration at the toes supports length-dependent neuropathy. ScienceDirect
Ocular saccade testing. Dysmetric saccades (overshoot/undershoot) align with cerebellar vermis involvement. GARD Information Center
C) Laboratory and pathological tests
Liver panel with γ-GT. In CALFAN, γ-GT is low or normal despite cholestasis, which is a diagnostic clue; bilirubin and transaminases rise in crises. Nature
Coagulation profile (INR/PT, aPTT, fibrinogen). Detects liver synthetic failure and bleeding risk during episodes. Nature
Serum bile acids and ammonia. Elevated in cholestasis and liver failure; guide encephalopathy management. Nature
Infectious work-up during crises. Viral hepatitis panel and sepsis screening, because fevers often precede decompensation. Nature
Genetic testing for SCYL1. Targeted SCYL1 sequencing or exome panels confirm the diagnosis and inheritance. NCBI
Liver biopsy (selected cases). May show cholestasis and fibrosis; used when genetics are pending or unclear. GARD Information Center
D) Electrodiagnostic tests
Nerve conduction studies (NCS). Document length-dependent axonal motor-sensory neuropathy (reduced amplitudes). ScienceDirect
Electromyography (EMG). Supports neuropathy pattern and helps exclude primary muscle disease. ScienceDirect
Electroencephalogram (EEG) if encephalopathy or seizures. Not specific to CALFAN but assesses brain function during hepatic crises. (General practice in pediatric acute liver failure.) OAText
E) Imaging tests
Brain MRI. Frequently shows non-progressive cerebellar vermis atrophy; sometimes optic-nerve thinning. These findings support the clinical picture of ataxia. ScienceDirectGlobal Genes
Additional helpful imaging in practice includes liver ultrasound/elastography to look for fibrosis and portal hypertension as the child grows. (Supportive of chronic liver disease course reported in CALFAN.) GARD Information Center
Non-pharmacological treatments
(15 physiotherapy items, plus mind–body supports, “gene therapy” context, and educational/rehabilitation therapies)
Physiotherapy & movement rehabilitation
Task-specific balance training
Description (≈150 words): A structured program that repeatedly practices standing, stepping, turning, and obstacle negotiation on stable and unstable surfaces to retrain the cerebellum and peripheral feedback loops. Sessions might include tandem walking, single-leg stance with support, and graded challenges using foam pads or balance boards. The therapist adjusts difficulty to keep tasks safe yet challenging, with harness support if needed. Home exercise “micro-sessions” (3–5 minutes, several times daily) help reinforce gains.
Purpose: Reduce falls, improve gait stability, and shorten recovery time after intercurrent illnesses.
Mechanism: Repetitive practice drives motor learning and sensory reweighting, compensating for cerebellar deficits and reduced proprioception from neuropathy.
Benefits: Better confidence, steadier walking, more independence in daily activities.Gait training with cueing
Description: Therapists use rhythmic auditory cues (metronome, clap, music) and visual floor markers to regularize step length and timing. They may add treadmill training with body-weight support to safely increase step counts.
Purpose: Normalize cadence and step symmetry.
Mechanism: External cues bypass impaired internal timing networks in cerebellar ataxia and help integrate sensory feedback despite neuropathy.
Benefits: Smoother gait, fewer stumbles, improved endurance.Proprioceptive/strength program for distal legs
Description: Progressive resistance for ankle dorsiflexors, plantarflexors, and evertors using bands, ankle weights, and closed-chain drills (mini-squats, heel-toe raises). Includes vibration or textured insoles to enhance sensory input.
Purpose: Counter foot drop and ankle instability.
Mechanism: Hypertrophy and neuromuscular recruitment improve joint control when nerve signaling is reduced.
Benefits: Safer ambulation, easier stair climbing.Ankle–foot orthoses (AFOs)
Description: Custom lightweight braces that maintain the ankle at neutral, prevent toe-drag, and stabilize the foot.
Purpose: Immediate mechanical correction for foot drop and mediolateral ankle wobble.
Mechanism: External support substitutes for weak dorsiflexors and impaired proprioception.
Benefits: More predictable foot clearance, lower fall risk, less fatigue.Coordination drills (Frenkel-style)
Description: Slow, visually guided limb movements in lying/sitting/standing to reduce dysmetria and tremor.
Purpose: Improve endpoint accuracy.
Mechanism: Visual feedback compensates for cerebellar timing errors.
Benefits: Better reaching, dressing, and utensil use.Core and proximal stability training
Description: Exercises for trunk and hip stabilizers (bridging, side planks with support, bird-dog with assistance).
Purpose: Provide a stable base for limb control.
Mechanism: Proximal stability enhances distal motor output and balance.
Benefits: Fewer trunk sways, improved transfers.Dual-task training
Description: Combine walking with simple cognitive tasks (naming colors/animals) to practice divided attention in safe settings.
Purpose: Reduce real-world fall risk.
Mechanism: Trains shared attentional resources and motor planning.
Benefits: More resilient gait in busy environments.Sit-to-stand practice with variable surfaces
Description: Reps from chairs of different heights with supervised speed changes.
Purpose: Strengthen quadriceps and gluteals; improve function.
Mechanism: Task-specific strengthening.
Benefits: Easier transfers, toileting, and independence.Tremor-targeted limb weighting (trialed sparingly)
Description: Light wrist/ankle weights during activities.
Purpose: Dampen end-point tremor.
Mechanism: Alters limb inertia to smooth oscillations.
Benefits: Cleaner handwriting/scooping—if tolerated.Respiratory physiotherapy (when deconditioned)
Description: Incentive breathing games, bubble PEP, paced stair work.
Purpose: Maintain endurance, reduce infection risk.
Mechanism: Improves ventilation and airway clearance.
Benefits: Better exercise tolerance.Constraint-supported practice for the weaker side
Description: Guided tasks that favor the weaker limb (with safety).
Purpose: Address asymmetry from neuropathy.
Mechanism: Use-dependent plasticity.
Benefits: More symmetric function.Aquatic therapy
Description: Buoyancy-assisted gait and balance work in warm water.
Purpose: Low-impact practice with reduced fall risk.
Mechanism: Hydrostatic support enables longer practice.
Benefits: Endurance, confidence, joint comfort.Sensory re-education for feet
Description: Texture boxes, vibration, temperature discrimination games.
Purpose: Recalibrate cutaneous feedback.
Mechanism: Repetitive sensory input fosters cortical remapping.
Benefits: Safer walking, better foot placement.Functional electrical stimulation (FES) for foot drop (case-by-case)
Description: Peroneal-nerve stimulators cue dorsiflexion during swing phase.
Purpose: Improve toe clearance.
Mechanism: Timed stimulation substitutes for weak nerves/muscles.
Benefits: Fewer trips; not all children tolerate electrodes.Home safety modification & falls program
Description: Remove trip hazards, install rails, use night lighting; teach safe fall techniques and recovery.
Purpose: Prevent injuries.
Mechanism: Environmental and behavioral risk reduction.
Benefits: Fewer accidents, greater independence.
These rehabilitation strategies are widely used across pediatric ataxias and hereditary neuropathies and adapted to SCYL1-related disease because controlled trials in this ultra-rare condition are not yet available.
Mind–body supports
Fatigue-management pacing
Description: Plan the day in energy “blocks,” placing harder tasks after rest, and using mobility aids for longer distances.
Purpose/Mechanism: Reduces overexertion that worsens ataxia and fall risk; supports autonomic stability.
Benefits: More schooling and play with fewer crashes.CBT-informed coping skills for chronic illness
Description: Age-appropriate cognitive and behavioral tools for fear of falls, medical procedures, and hospitalizations.
Purpose/Mechanism: Reframes catastrophic thoughts and builds problem-solving; reduces anxiety-linked motor worsening.
Benefits: Better engagement with therapy and school.Mindful breathing & relaxation
Description: Short guided breathing (box breathing, bubble blowing).
Purpose/Mechanism: Lowers sympathetic arousal that can destabilize tremor and sleep.
Benefits: Calmer movement, improved sleep onset.Sleep hygiene coaching
Description: Consistent schedule, light control, screens off, soothing routines.
Purpose/Mechanism: Rest supports motor learning and immune resilience.
Benefits: Fewer illness triggers, better therapy carryover.Family peer-support linkage
Description: Connect with rare disease networks and counseling.
Purpose/Mechanism: Reduces isolation; improves adherence.
Benefits: Practical tips, emotional resilience.
“Gene therapy” context (educational; not a current treatment to self-start)
Genetic counseling & research enrollment
Description: Families learn inheritance risks; clinicians may discuss natural-history registries or early-phase trials as they emerge.
Purpose/Mechanism: Supports informed family planning; advances knowledge.
Benefits: Access to updates and expert centers. At present, there is no approved gene therapy for SCYL1; approaches remain investigational. PMC
Educational & allied therapies
Occupational therapy (OT) for fine-motor skills
Description: Adaptive pencils, weighted utensils, button hooks, and step-by-step practice for dressing and self-care.
Purpose/Mechanism: Task simplification and compensatory strategies.
Benefits: Independence with feeding/schoolwork.Speech-language therapy
Description: Breath-voice coordination, pacing for dysarthria, and language supports for any learning delays.
Purpose/Mechanism: Motor speech practice with external cues.
Benefits: Clearer communication, less frustration.Individualized Education Program (IEP/504)
Description: School-based accommodations (extra time, mobility support, elevator access, reduced-volume handwriting).
Purpose/Mechanism: Removes barriers to learning.
Benefits: Better academic participation.Nutrition consult (cholestasis-aware)
Description: Adequate calories with medium-chain triglycerides (MCTs), fat-soluble vitamin supplementation (A, D, E, K), and sick-day plans to maintain glucose and fluids.
Purpose/Mechanism: Bypasses bile-dependent fat absorption and prevents deficiencies.
Benefits: Growth support and lower complication risk. NASPGHAN
Drug treatments
Critical safety note: All pediatric medications require clinician oversight with weight-based dosing and adjustments for liver function. Some drugs below are contraindicated during active liver failure or used only in intensive care.
N-acetylcysteine (NAC) – antidote/antioxidant
Use: Standard of care for acetaminophen toxicity and often used in non-acetaminophen pediatric ALF. Purpose: Support glutathione and microcirculation. Mechanism: Replenishes glutathione; improves hepatic perfusion. Timing: Early in ALF (ICU). Side effects: Nausea, rare anaphylactoid reactions. PMCVitamin K (parenteral or oral when safe) – hemostasis
Use: Corrects vitamin-K–dependent coagulopathy from cholestasis or ALF (if not due to synthetic failure alone). Mechanism: Cofactor for γ-carboxylation of clotting factors. Benefits: Reduces bleeding risk; assess with INR. Side effects: Injection discomfort; rare allergy. NASPGHANUrsodeoxycholic acid (UDCA) – choleretic
Use: In cholestatic phases to improve bile flow and pruritus. Mechanism: Hydrophilic bile acid; cytoprotective. Side effects: Diarrhea; monitor LFTs. (Use is clinician-specific in ALF context.) NASPGHANRifampin – antipruritic via enzyme induction
Use: Severe cholestatic itch not controlled by other measures. Mechanism: Induces hepatic enzymes; modulates bile acid signaling. Cautions: Hepatotoxicity risk—avoid in active ALF; monitor LFTs. NASPGHANCholestyramine or colesevelam – bile-acid sequestrants
Use: Itch relief in cholestasis. Mechanism: Binds bile acids in gut. Side effects: Constipation, vitamin deficiency; separate from other meds. NASPGHANLactulose – encephalopathy management
Use: For hepatic encephalopathy to reduce ammonia. Mechanism: Traps ammonia in the gut as ammonium; laxative effect. Side effects: Diarrhea, dehydration—dose carefully in children. NASPGHANRifaximin – adjunct for encephalopathy (older children)
Mechanism: Non-absorbed antibiotic reducing ammonia-producing bacteria. Caution: Off-label pediatric use; adjust with specialist. NASPGHANHypertonic saline or mannitol (ICU) – cerebral edema in severe ALF
Mechanism: Osmotherapy lowers intracranial pressure. Use: With neuro-monitoring in ICU. Risks: Electrolyte shifts, renal strain; invasive monitoring sometimes used. NASPGHANProton-pump inhibitor (or H2 blocker) – GI bleed prophylaxis in ALF
Purpose: Stress ulcer prevention. Caution: Balance infectious risks. aasld.orgBroad-spectrum antibiotics (when infection suspected)
Use: Fever often triggers liver crises; early evaluation and targeted therapy are key. Mechanism: Treats bacterial triggers/sepsis. Caution: Stewardship principles; culture-guided. aasld.orgGabapentin – neuropathic pain
Use: Limb discomfort, paresthesia. Mechanism: α2δ calcium-channel modulation. Caution: Sedation, dose adjust in renal issues; consider liver status.Amitriptyline (older children/adolescents, specialist use) – neuropathic pain/sleep
Mechanism: Tricyclic; descending inhibitory pathways. Cautions: Anticholinergic effects; ECG if needed; hepatic metabolism—use only if liver stable.Pregabalin (adolescents/weight-based) – neuropathic pain
Mechanism: α2δ modulation similar to gabapentin. Caution: Dizziness, edema; titrate carefully.Sertraline or naltrexone for refractory cholestatic itch (specialist use)
Mechanism: Central itch pathway modulation (sertraline) or opioid receptor antagonism (naltrexone). Caution: Hepatic metabolism—avoid during ALF; monitor closely. NASPGHANAcetaminophen/NSAIDs for fever— only per hepatology plan
Context: Because fever can precipitate crises yet many antipyretics carry liver/bleeding risks, families should follow a personalized fever protocol (often emphasizing physical cooling first; medications only if approved by the team). Never self-dose during a suspected ALF episode. aasld.org
Dietary “molecular” supplements
Evidence ranges from expert-consensus pediatric liver care to limited pediatric studies; always coordinate with your hepatology dietitian.
Fat-soluble vitamins A, D, E, K – replace losses from cholestasis; use water-miscible formulations; monitor levels to avoid toxicity. NASPGHAN
Medium-chain triglyceride (MCT) oil – improves calorie absorption when bile flow is reduced; mix into foods. NASPGHAN
Calcium + vitamin D3 – bone protection when vitamin D is low; weight-based dosing guided by labs. NASPGHAN
Essential fatty acids (omega-3s/DHA) – may support neurodevelopment and anti-inflammatory balance; monitor bleeding risk.
Choline – supports liver lipid export and myelination; dietitian-directed dose.
S-adenosyl-L-methionine (SAMe) – methyl donor with hepatocellular antioxidative roles; specialist-guided use.
L-carnitine – mitochondrial fatty-acid transport; sometimes used in pediatric metabolic liver care; monitor for GI upset.
Thiamine (vitamin B1) – supports energy metabolism; low risk with oversight.
Folate/B12 as needed – neuropathy workups often screen and replete deficiencies.
Zinc – may aid ammonia handling and wound healing; check levels first.
Immunity-booster / regenerative / stem-cell” therapies
Standard immunizations and seasonal vaccines
Function: Reduce fever/infection triggers that precipitate liver crises. Mechanism: Adaptive immunity to common pathogens. Note: Coordinate with hepatology on timing during/after ALF. aasld.orgPassive immunization (e.g., RSV monoclonal per guidelines)
Function: Lower risk of severe viral illness in eligible infants. Mechanism: Pathogen-specific antibodies.Hepatocyte transplantation (investigational/center-specific)
Function: Bridge therapy for liver failure while native liver recovers. Mechanism: Infused donor hepatocytes provide temporary metabolic support. Status: Research/selected centers only. NASPGHANMesenchymal stromal cell infusions (experimental)
Function: Anti-inflammatory and trophic support. Mechanism: Paracrine effects that may modulate immune injury. Status: Clinical trials only; not standard care.Gene-targeted approaches for SCYL1 (preclinical/early research)
Function/Mechanism: Potential correction or functional rescue of SCYL1 pathways. Status: No approved therapy; consider registry participation. PMCNeuroregenerative rehabilitation (intensive blocks)
Function: While not a “drug,” high-frequency therapy blocks can drive neuroplasticity, the most realistic regenerative strategy available now. Mechanism: Activity-dependent synaptic strengthening.
Procedures/surgeries
Orthopedic tendon transfer or ankle stabilization
Procedure: Rebalance tendons to improve active dorsiflexion and correct foot drop when bracing fails in older children.
Why: Improve safety and gait mechanics in significant neuropathic weakness.Gastrostomy tube (G-tube)
Procedure: Feeding tube placement when oral intake is unsafe/insufficient during prolonged illness or severe dysphagia.
Why: Secure nutrition, medications, and supplements.Liver transplantation
Procedure: Donor liver replacement.
Why: Only if liver failure becomes irreversible or chronic decompensation occurs; many SCYL1 cases recover between episodes, so transplant is individualized. aasld.orgScoliosis correction (if progressive)
Procedure: Posterior spinal instrumentation in selected cases with significant scoliosis from neuropathic weakness.
Why: Pain control, pulmonary protection, sitting balance.Implantable venous access (port)
Procedure: Port placement for repeated hospital therapies when needed.
Why: Reduce repeated needle sticks and maintain reliable access during crises.
Prevention strategies
Fever action plan (written) with thresholds for ED/ICU contact. aasld.org
Up-to-date immunizations and sick-day precautions. aasld.org
Prompt evaluation of infections—don’t “wait it out” in high-risk children. aasld.org
Avoid hepatotoxins (unprescribed herbal products, high-dose vitamin A, alcohol in teens). aasld.org
Medication list review at every visit for liver dosing/contraindications. NASPGHAN
Hydration and carbohydrate support during illness to avoid hypoglycemia. aasld.org
Nutrition plans with MCT and vitamins in cholestasis. NASPGHAN
Home safety & falls prevention as mobility changes.
Regular liver and neuro follow-up (LFTs, INR, growth, physio reassessments). NASPGHAN
School coordination (IEP/504) to prevent setbacks in learning and participation.
When to see doctors
Any fever or suspected infection in a diagnosed child (or child under evaluation) because fever can trigger acute liver failure. aasld.org
Vomiting, lethargy, confusion, new sleepiness, irritability, or unusual behavior (possible encephalopathy). NASPGHAN
Jaundice intensifying, very dark urine, pale stools, or bruising/bleeding. NASPGHAN
Rapidly worsening unsteadiness, repeated falls, or new weakness/numbness in limbs.
Poor feeding, dehydration, or hypoglycemia signs (sweats, tremor). aasld.org
What to eat and what to avoid
What to eat:
Energy-dense meals with MCT-enriched fats during/after illness. NASPGHAN
Balanced protein appropriate for age (do not restrict without medical advice).
Colorful fruits/vegetables for micronutrients and fiber.
Whole-grain starches for steady glucose.
Vitamin-fortified formulas or shakes if growth falters (dietitian-guided).
What to avoid or limit:
- Unverified herbal supplements (risk of hepatotoxicity). aasld.org
- Very high vitamin A or niacin doses unless prescribed (liver toxicity). NASPGHAN
- Raw or undercooked shellfish (hepatitis-A/Vibrio risks).
- Sugar-only drinks that displace nutrition (except during specific hypoglycemia plans).
- Ultra-processed, very salty snacks that worsen fluid retention during illness.
Frequently Asked Questions
What causes this syndrome?
Biallelic (both-copy) pathogenic variants in SCYL1 disrupt intracellular trafficking, particularly in liver and cerebellar neurons. PMCIs it inherited?
Yes. It’s autosomal recessive—parents are typically healthy carriers; each pregnancy has a 25% chance to be affected. National Organization for Rare DisordersWhy do liver crises happen with fever?
Fever/infections increase metabolic and immune stress that the vulnerable liver cannot handle, leading to acute injury. aasld.orgDo children recover between episodes?
Often yes; many have full biochemical recovery, though some develop scarring over time. PMCWill my child always have coordination problems?
Ataxia usually persists but can be improved functionally with rehabilitation; progression varies. PMCIs neuropathy painful?
It can cause numbness, tingling, or discomfort; neuropathic pain medicines and therapy help many children.Is liver transplant inevitable?
No. Transplant is case-by-case; many children improve between crises. Early transfer to a transplant-capable center during episodes is recommended. aasld.orgHow is it diagnosed?
Clinical triad plus tests: liver labs, nerve conduction studies, brain MRI, and genetic testing confirming SCYL1 variants. PMCHow common is it?
Extremely rare; most information comes from small case series and reports. PMCIs there a cure?
No gene-based cure yet; treatment is supportive and preventive. Research is ongoing. PMCCan we prevent episodes?
We can lower risk by infection prevention, rapid care for fever, nutrition plans, and avoiding hepatotoxins. aasld.orgWhat specialists are involved?
Pediatric hepatology/transplant, neurology/physiatry, genetics, nutrition, PT/OT/SLP, psychology, and school-based services. NASPGHANAre other genes similar?
Yes—NBAS deficiency also causes fever-triggered ALF but with different associated features. PMCWhat monitoring is typical?
Regular LFTs/INR, growth/nutrition checks, vitamin levels in cholestasis, neuro/physio assessments, and school progress reviews. NASPGHANWhere can I read more?
Authoritative summaries exist via Orphanet and NIH/GARD; clinicians may share key research papers on SCYL1/CALFAN. OrphaGARD Information CenterPMC
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: September 06, 2025.
